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Background: Alterations in TNF-α expression have been associated with cerebral aneurysms, but a direct role in
formation, progression, and rupture has not been established.
Methods: Cerebral aneurysms were induced through hypertension and a single stereotactic injection of elastase
into the basal cistern in mice. To test the role of TNF-α in aneurysm formation, aneurysms were induced in TNF-α
knockout mice and mice pretreated with the synthesized TNF-α inhibitor 3,6′dithiothalidomide (DTH). To assess the
role of TNF-α in aneurysm progression and rupture, DTH was started 6 days after aneurysm induction. TNF-α expression
was assessed through real-time PCR and immunofluorescence staining.
Results: TNF-α knockout mice and those pre-treated with DTH had significantly decreased incidence of aneurysm
formation and rupture as compared to sham mice. As compared with sham mice, TNF-α protein and mRNA expression
was not significantly different in TNF-α knockout mice or those pre-treated with DTH, but was elevated in unruptured
and furthermore in ruptured aneurysms. Subarachnoid hemorrhage (SAH) occurred between 7 and 21 days following
aneurysm induction. To ensure aneurysm formation preceded rupture, additional mice underwent induction and
sacrifice after 7 days. Seventy-five percent had aneurysm formation without evidence of SAH. Initiation of DTH
treatment 6 days after aneurysm induction did not alter the incidence of aneurysm formation, but resulted in
aneurysmal stabilization and a significant decrease in rupture.
Conclusions: These data suggest a critical role of TNF-α in the formation and rupture of aneurysms in a model
of cerebral aneurysm formation. Inhibitors of TNF-α could be beneficial in preventing aneurysmal progression
and rupture.
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Cerebral aneurysm rupture is associated with significant
morbidity and mortality [1,2]. A significant number of
patients may be treated with microsurgery or endovascu-
lar coiling, but intervention is not without the risk of
neurological injury [1,2]. A large number of patients are
followed clinically as they are deemed either at lower
risk of hemorrhage or at high risk for treatment. Even in* Correspondence: bobby.starke@gmail.com
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unless otherwise stated.these cohorts, a significant number of patients will go
on to have aneurysmal rupture or receive treatment for
aneurysm progression despite originally being consid-
ered high risk for intervention or low risk of rupture
[2,3]. Medical therapy that stabilizes aneurysmal pro-
gression or rupture could be beneficial for a significant
number of patients. Currently, there are no pharmaco-
logical alternatives for patients with cerebral aneurysms.
Inflammation has been implicated in the pathogenesis
of intracranial aneurysm formation and rupture [4]. Al-
terations in TNF-α have been associated with cerebral
aneurysm in humans [5,6], but a direct role in aneurysm
formation or rupture has not been defined. TNF-α is a
critical member of the immune system [7] and producestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cerebral aneurysms including macrophages, endothelial
and smooth muscle cells [8-10].
The goals of the present study were to: 1) assess the
direct role TNF-α in a model of cerebral aneurysm
formation; 2) determine if there are alterations in
TNF-α expression in cerebral aneurysm formation and
rupture; 3) evaluate if TNF-α inhibition decreases the
incidence of aneurysm formation; and 4) test whether
TNF-α inhibition after cerebral aneurysm formation
may lead to aneurysm stabilization and inhibition of
rupture.
Methods
This study was carried out in accordance with the rec-
ommendations in the Guide for the Care and Use of La-
boratory Animals of the National Research Council [11].
The protocol was approved by the Institutional Animal
Care and Use Committee of Thomas Jefferson University
(Philadelphia, PA, USA). Cerebral aneurysms were induced
in 8- to 10-week-old male TNF-α gene null (TNF-α −/−)
mice (on C57BL/6 J background) or their wild type con-
trols (Jackson Laboratory, Bar Harbor, ME, USA) using
previously described methods [9,12,13] with alterations as
herein described.
To induce hypertension, mice underwent nephrectomy
followed by implantation of deoxycorticosterone acetate
pellet (Innovative Research of America, Sarasota, FL,
USA) 1 week later [14]. On the same day as deoxycor-
ticosterone acetate pellet implantation, animals were
started on water containing 1% NaCl (Sigma-Aldrich, St
Louis, MO, USA) to induce hypertension [9,12-14] and
0.12% beta-aminoproprionitrile (BAPN; Sigma-Aldrich)
to reduce collagen cross-linking [15]. Elastase (Sigma-
Aldrich) was prepared in sterile PBS (Sigma-Aldrich).
Mice underwent a single stereotactic elastase injection
(35 mU) into the cerebrospinal fluid at the right basal
cistern on the same day as pellet implantation [9,12,13].
Sham control mice received a single stereotactic injec-
tion of PBS. A single stereotactic injection of dye was
performed for every 10 mice to ensure accurate needle
placement. Animals were assigned to the sham or
aneurysm induction cohorts randomly in an alternating
fashion.
Blinded daily neurological examination was carried out
using a previously described method [13,16-18]. Neuro-
logical symptoms were graded: 0, normal; 1, decreased
drinking or eating with associated weight loss >2 g of
body weight (approximately 10%) over 24 hours; 2, flexion
of the torso and forelimbs on lifting of the animal by the
tail; 3, circling to one side with a normal posture at rest; 4,
leaning or falling to one side at rest; 5, no spontaneous
activity. Mice were euthanized when they developedneurological symptoms (score 1 to 5). All asymptomatic
mice were euthanized 28 days after aneurysm induction.
The brain samples were perfused with PBS followed by a
gelatin (Sigma-Aldrich) containing blue dye to visualize
cerebral arteries as well as to assess for aneurysm forma-
tion and subarachnoid hemorrhage (SAH). Aneurysms
were defined as a localized outward bulging of the vascu-
lar wall whose diameter was greater than 1.5 times the
parent artery diameter by two independent observers
blinded to the animal cohort [12,13]. Animal cohorts
were not revealed until all experimental groups had
been sacrificed.
Systolic blood pressure was measured by the tail-cuff
method with the BP-2000 Blood Pressure Analysis System
(Visitech Systems, Apex, NC, USA) after 3 days of training
to allow for acclimation and then before aneurysm in-
duction surgery (day 0) and every week until day 28 after
surgery [19].Treatment with 3,6′dithiothalidomide (DTH)
To test whether TNF-α inhibition decreased the incidence
of cerebral aneurysm formation, progression, and rupture,
the TNF-α inhibitor 3,6′dithiothalidomide (DTH) was
synthesized as previously described [20,21] and was
greater than 99% purity. Sham animals and TNF-α knock-
out animals received intraperitoneal vehicle (1% carboxy-
methyl cellulose solution (Fluka, Sigma-Aldrich) prepared
in sterile saline) and animals undergoing aneurysm induc-
tion surgery received intraperitoneal injections of the syn-
thesized TNF-α inhibitor DTH [20,21], prepared as a
suspension in the vehicle at a dose of 56 mg/kg. Dosing
was based on preliminary studies and prior experiments
[8,21]. To test whether TNF-α inhibition decreased the in-
cidence of cerebral aneurysm formation, DTH treatment
was started 3 days prior to elastase injection and contin-
ued for 28 days. To test whether TNF-α inhibition re-
sulted in aneurysm stabilization and inhibition of rupture,
DTH was started 6 days after elastase injection.Quantitative real-time PCR and immunohistochemistry
Quantitative real-time PCR and immunohistochemistry
were carried out as previously described [8,22]. Details
can be found in Additional file 1: Quantitative real-time
PCR and immunohistochemistry.Statistical analysis
Primary outcomes were the incidence of aneurysm forma-
tion (both ruptured and unruptured) and the incidence of
ruptured aneurysms. Further description of the methods
of statistical analysis can be found in Additional file 1:
Statistical analysis.
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Potential role of TNF-α in the formation of intracranial
aneurysms
To test the role of TNF-α in the formation of intracra-
nial aneurysms, the TNF-α inhibitor DTH was synthe-
sized as previously described [20,21] to greater than 99%
purity. Animals began treatment with DTH 3 days prior
to elastase injection and were compared to both mice re-
ceiving vehicle undergoing aneurysm induction and
TNF-α knockout mice undergoing aneurysm induction.
TNF-α knockout mice, those treated with DTH, and
those treated only with vehicle undergoing aneurysm in-
duction had significant increases in systolic blood pres-
sure 7 days after elastase injection that was sustained
until 28 days, but was not significantly different between
the three cohorts at any time point (Figure 1).
Cerebral aneurysm formation occurred in 18 of 22
(81.8%) animals receiving only vehicle as compared to 3
of 12 TNF-α knockout mice (25%, P = 0.002) and 4 of 12
mice (33%, P = 0.008) treated with DTH (Figure 2A).
The incidence of ruptured aneurysm was also signifi-
cantly increased in those receiving vehicle (15 of 22,
68.2%) as compared with TNF-α knockout mice (1 of
12, 8.3%; P = 0.001) and those receiving DTH (3 of 12,
25%, P = 0.030; Figure 2B). Animals developed new
neurological signs (score 1 to 5) and aneurysmal SAH
between 7 and 21 days (Figure 2C). TNF-α knockout
mice were 12.4 times (95% CI 1.6 to 94.2, P = 0.015) and
those treated with DTH were 4.1 times (95% CI 1.2 to
14.1, P = 0.028) less likely to have aneurysm rupture as
compared to mice receiving vehicle.
TNF-α expression in unruptured and ruptured intracranial
aneurysms
Figure 3A shows the normal brain vasculature from a
mouse following sham surgery. This was not significantly
different from mice pre-treated with DTH or TNF-α
knockout mice (Additional file 1: Figure S1). AnFigure 1 Blood pressure analysis. Blood pressure was elevated
1 week after aneurysm induction, but was not significantly different
between mice pre-treated with DTH, TNF-α knockout mice, and mice
receiving vehicle alone. DTH, 3,6'dithiothalidomide.unruptured intracranial aneurysm from a mouse sacrificed
on day 28 is depicted in Figure 3B. Figure 3C demon-
strates a ruptured intracranial aneurysm that was found
on post-operative day 12 following aneurysm induction in
a mouse that presented with acute onset of crouching and
hemiparesis manifesting as circling to the right. Most of
the aneurysms were larger than 500 μm, approximately 3
to 5 times larger than their parent arteries.
Histological assessment of the aneurysms demonstrated
structural changes that were similar to those found in hu-
man cerebral aneurysms (Figure 3) [12,23]. H & E and tri-
chrome staining of cerebral vessels from sham operated
mice demonstrated two to three layers of smooth muscle
cells and a single layer of continuous endothelial cells (A2
to 5). Trichrome staining demonstrated one layer of elastic
lamina as previously noted (A4 to 5) [12]. In intracranial
aneurysms, there were layers of discontinuous endothelial
cells and scattered smooth muscle cells (B2 to 5 and C2 to
5). Trichrome staining revealed disorganized elastic lam-
ina (B4 to 5 and C4 to 5).
As alterations in TNF-α have been associated with hu-
man intracranial aneurysms [5,6], we sought to assess al-
terations in expression of TNF-α in this animal model of
cerebral aneurysms. As compared to sham mice, there
was no difference in immunofluorescence reactivity when
comparing TNF-α knockout mice or those treated with
DTH (Additional file 1: Figure S1). TNF-α expression was
higher in unruptured aneurysms and highest in ruptured
aneurysms (Figure 3), but this may be due to inflamma-
tion caused by SAH rather than increased TNF-α expres-
sion leading to aneurysmal rupture. As we have previously
found that smooth muscle cells can produce TNF-α [8],
we sought to determine the source of TNF-α. To localize
TNF-α expression, samples were co-stained with either
SMC-22α for smooth muscle cells or CD-68 for macro-
phages (Figure 3). TNF-α expression co-localized to both
smooth muscle cells and macrophages in both unruptured
(B6 to 7) and ruptured aneurysms (C6 to 7). Normal sized
cerebral blood vessels also stain only red for SM-22α in
vascular segments adjacent to cerebral aneurysms (B6).
There were more macrophages in ruptured aneurysms
(C7) as compared to unruptured aneurysms (B7) and an
absence of macrophages in sham operated mice (A7).
Similarly, as compared with sham mice, real-time PCR
demonstrated no significant difference in TNF-α mRNA
expression of cerebral blood vessels from TNF-α knockout
mice or those treated with DTH (Figure 4). TNF-α mRNA
extracted from unruptured, and even more so in ruptured
aneurysms, was significantly elevated as compared with
sham mice (Figure 4). As a secondary control, beta-actin
expression was assessed and found to be not significantly
different between sham mice, TNF-α knockout mice, mice
treated with DTH, unruptured aneurysm, and ruptured
aneurysms (Additional file 1: Figure S2).
Figure 2 (See legend on next page.)
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Figure 2 The role of TNF-α in the formation of intracranial aneurysms. (A) Cerebral aneurysm formation was significantly increased in mice
receiving vehicle as compared to TNF-α knockout mice and those pre-treated with DTH. (B) The incidence of aneurysm rupture was also significantly
increased in mice receiving vehicle versus TNF-α knockout mice and those pre-treated with DTH. (C) Kaplan-Meier analysis demonstrates that
aneurysm rupture occurred between 7 and 21 days following aneurysm induction, and mice receiving vehicle were more likely to have ruptured
aneurysms as compared to TNF-α knockout mice and those pre-treated with DTH. DTH, 3,6'dithiothalidomide.
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Prior studies have found that cerebral aneurysm forma-
tion in a similar model of aneurysm formation occurs
between 7 and 21 days [13]. To further define the time
course of aneurysm formation and verify that aneurysmal
formation occurs prior to aneurysmal rupture, eight add-
itional mice underwent aneurysm induction. None of the
mice developed neurological alterations during this time
period. Mice were euthanized 7 days after elastase injec-
tion at a time point before aneurysm rupture in the prior
cohort of animals. Six of eight animals (75%) formed an-
eurysms and none had evidence of aneurysmal rupture.
The overall incidence of aneurysm formation in this co-
hort was similar to the rate of aneurysms in the prior
untreated cohort (81.8%). Additionally, this confirms
that from day 7 to day 21 appears to represent a time-
frame during which medical therapies targeting aneurysm
stabilization can be tested without altering the formation
of aneurysms.
Effect of TNF-α inhibition on the incidence of aneurysm
rupture
To test whether TNF-α inhibition could stabilize aneurysm
progression and decrease the incidence of aneurysm rup-
ture, DTH was started 6 days after elastase injection. Those
treated with DTH and mice receiving vehicle undergoing
aneurysm induction had significant increases in systolic
blood pressure 7 days after elastase injection that
was sustained until 28 days, but was not significantly
different between the two cohorts at any time point
(Figure 5).
There was no significant difference in the overall inci-
dence of aneurysm formation between cohorts treated
with DTH (9 of 12, 75%) and those treated with vehicle
(18 of 22, 83%, P = 0.678; Figure 6A). The incidence of
rupture was significantly decreased in those treated with
DTH (2 of 12, 16.7%) as compared to vehicle (15 of 22,
68.2%, P = 0.010; Figure 6B). Additionally, the rate of
cerebral aneurysm rupture in those with cerebral
aneurysm formation was significantly decreased in those
treated with DTH (2 of 9, 22.2%) as compared with
vehicle (15 of 18, 83.3%, P = 0.037; Figure 6C). A
symptom-free Kaplan-Meier analysis was carried out to
determine the effect of DTH on the overall incidence of
rupture. After eliminating those animals without
aneurysmal formation, those receiving delayed DTH
treatment were 5.8 times less likely to have aneurysmalrupture than those receiving vehicle (95% CI 1.3 to 25.5,
P = 0.020; Figure 6D).
Discussion
Cerebral aneurysm rupture leads to disability or death in
the majority of patients [1,2]. Treatment is also associ-
ated with significant morbidity and mortality, particu-
larly in high risk aneurysms or patients [1,2]. Although
intervention is controversial in select patients with
unruptured aneurysms, studies have found that a large
number of patients deemed low risk of hemorrhage or
high risk for treatment may go on to receive treatment
for aneurysm progression or experience SAH [2,3]. Cur-
rently, there are no medical therapies in clinical practice
to stabilize aneurysmal progression or prevent rupture.
In this study we have found that the expression of the
pro-inflammatory cytokine TNF-α is increased in a
mouse model of cerebral aneurysms. This expression is
increased in unruptured cerebral aneurysms and further-
more in ruptured aneurysms. The incidence of cerebral
aneurysm formation and rupture was decreased in TNF-
α knockout mice and following pre-treatment with a
synthesized TNF-α inhibitor. The TNF-α inhibitor also
resulted in aneurysm stabilization and decreased rupture
after aneurysm formation.
TNF-α has also been found to be elevated in humans
with ruptured cerebral aneurysms [5,6], but mechanisms
behind TNF-α activation in cerebral aneurysms are cur-
rently unclear. A number of environmental factors asso-
ciated with cerebral aneurysm formation have been
implicated in TNF-α activation. We have previously
found that induced hypertension in conjunction with
hemodynamic stress in rats in vivo can increase the ex-
pression of TNF-α [8]. We have also found that TNF-α
is upregulated following exposure of cultured cerebro-
vascular smooth muscle cells to cigarette smoke [22,24],
and others have found increased expression of TNF-α in
blood vessels following cigarette exposure [25]. Additional
risk factors associated with cerebral aneurysms, including
aging, gender, and alcohol, have also been associated with
TNF-α expression [4-6].
Environmental factors may activate TNF-α in both mac-
rophages and smooth muscle cells. In this study we have
found that TNF-α co-localized to both macrophages and
smooth muscle cells. We have previously found that
hypertension, hemodynamic stress, and cigarette smoke
may activate TNF-α and induce phenotypic modulation in
Figure 3 (See legend on next page.)
Starke et al. Journal of Neuroinflammation 2014, 11:77 Page 6 of 10
http://www.jneuroinflammation.com/content/11/1/77
(See figure on previous page.)
Figure 3 Cerebral aneurysm formation and rupture and TNF-α expression. Representative gross images of normal cerebral blood vessels in
(A) sham operated mice, (B) unruptured aneurysms, and (C) ruptured aneurysms. H & E staining of normal cerebral blood vessels in sham
operated mice demonstrates two to three layers of smooth muscle cells and a single, thin, continuous layer of endothelial cells (A2 to 3). In both
unruptured cerebral aneurysms (B2 to 3) and ruptured aneurysms (C2 to 3) there are thin and thick areas of vascular wall. In unruptured
aneurysms in the areas of thin vascular wall, there is intact endothelial and smooth muscle cell layers, but this is discontinuous in the areas of
thick vascular wall. In ruptured aneurysms these areas are sometimes discontinuous in both thick and thin areas of the vascular walls. Trichrome
staining of normal cerebral blood vessels in sham operated mice (A4 to 5) demonstrates one layer of elastic lamina. This is disorganized in
unruptured aneurysms (B4 to 5) and ruptured aneurysms (C2 to 3). TNF-α (green) expression is nearly non-existent in sham operated mice (A6 to 7).
The expression of TNF-α (green) is decreased in sham mice (A6 to 7) as compared to unruptured (B6 to 7) and furthermore ruptured aneurysms
(C6 to 7). SMC-22α (red) is observed in sham operated mice (A6) and co-localizes with TNF-α (green) to appear yellow in unruptured (B6) and
ruptured aneurysms (B7). Normal sized cerebral blood vessels also stain only red for SM-22α in vascular segments adjacent to cerebral aneurysms
(B6). Macrophages are nearly non-existent in sham operated mice (A7). Macrophages (red) co-localize with TNF-α (green) and appear yellow in
unruptured aneurysms (B7) and more so in ruptured aneurysms (C7). Nuclei are stained blue with DAPI. DAPI, 4',6-diamidino-2-phenylindole;
H & E, hematoxylin and eosin; SM-22α, smooth muscle cell 22 alpha.
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mechanisms by which TNF-α contributes to cerebral
aneurysm formation are not completely defined, inflam-
mation is a significant element behind the pathogenesis
of cerebral aneurysm formation [4], and TNF-α is a sig-
nificant pro-inflammatory immune modulator. We have
previously found that TNF-α can activate a number of
pro-inflammatory and matrix remodeling genes in cere-
bral vascular smooth muscle cells directly implicated in
cerebral aneurysm formation, including: MMP-3,
MMP-9, MCP-1, VCAM-1, and IL-1β [8]; and IL-1β,Figure 4 TNF-α mRNA expression. As compared with sham mice
receiving vehicle, real-time PCR demonstrated no significant difference
in TNF-α mRNA expression of cerebral blood vessels from TNF-α
knockout mice or those pre-treated with DTH, but TNF-α was significantly
elevated in unruptured and furthermore in ruptured aneurysms.
DTH, 3,6'dithiothalidomide.VCAM-1 and MCP-1 [9,26,27]. Specifically, increased
MCP-1 may attract macrophages leading to increased
TNF-α formation, and macrophages have previously
been found to be critical in the formation of cerebral
aneurysms [9]. Additionally, MCP-1 has been found to
be increased in aneurysm walls and MCP-1 knockout
mice had lower levels of matrix metalloproteinases
(MMPs), and a decreased incidence of aneurysm forma-
tion [26]. MMPs degrade the extracellular matrix [28]
and have been found to be increased in human cerebral
aneurysms [29]. Inhibition of MMPs has also been
shown to decrease the incidence of aneurysm formation
and progression in animals [12,13]. Although there are
likely many further key mediators, TNF-α may contrib-
ute to cerebral aneurysm formation through activation
of pro-inflammatory and matrix remodeling genes and
recruitment and activation of inflammatory cells.
The role of TNF-α in aneurysm progression and rupture
is unknown. Increased expression of TNF-α in human
[5,6] and mouse ruptured cerebral aneurysms may be a re-
flection of the inflammatory response following rupture
rather than a mechanism leading to aneurysm instability
and rupture. TNF-α is a key initiator of apoptosis [30,31]Figure 5 Blood pressure analysis in delayed DTH treatment.
Blood pressure was elevated 1 week after aneurysm induction,
but was not significantly different between mice treated with
DTH starting on day 7 and mice receiving vehicle alone.
DTH, 3,6'dithiothalidomide.
Figure 6 Aneurysm stabilization with DTH. (A) There was no significant difference in the overall incidence of aneurysm formation between
cohorts treated with DTH and those treated with vehicle. (B) The incidence of rupture was significantly decreased in those treated with DTH as
compared to vehicle. (C) The rate of cerebral aneurysm rupture in those with cerebral aneurysm formation was significantly decreased in those
treated with DTH as compared with vehicle. (D) After eliminating those animals without aneurysm formation, Kaplan-Meier analysis demonstrated
that those receiving delayed DTH treatment were 5.8 times (95% CI 1.3 to 25.5, P = 0.020) less likely to have aneurysmal rupture than those
receiving vehicle. DTH, 3,6'dithiothalidomide.
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domain) have been increased in human cerebral aneu-
rysms [5]. We have previously found that TNF-α triggers
apoptosis in a dose-dependent fashion in cultured cere-
brovascular smooth muscle cells [8], and this may contrib-
ute to both aneurysm progression and rupture through
loss of focal cerebrovascular contractility. This may be ex-
plained by the co-localization of TNF-α to smooth muscle
cells in cerebral aneurysms found in mice and ultimately
the loss of smooth muscle cells in unruptured and further-
more ruptured aneurysms. TNF-α-induced macrophage
infiltration and phagocytosis may also contribute to this
process [26,32] as the quantity of apoptotic cells has been
associated with cerebral aneurysm rupture [33,34] and
macrophage infiltration was increased furthermore in rup-
tured versus unruptured aneurysms.
Additional experiments are indicated both in vivo and
in humans to assess the role of TNF-α in cerebral
aneurysm progression and rupture. Further in vivo ex-
periments following upregulation of TNF-α both in wild
type and TNF-α knockout mice would be beneficial to
further clarify the molecular mechanisms downstream ofTNF-α upregulation in aneurysm formation and rupture.
Limitations of this study include detection of aneurysm
rupture through assessment of alterations in neuro-
logical examination, which may fail to detect subclinical
or asymptomatic hemorrhages. Despite this drawback,
examination of brains in asymptomatic mice did not re-
veal signs of significant SAH. Additionally, although
DTH has been found to be a specific inhibitor of TNF-α
synthesis [20,21], it may have additional properties that
contribute to inhibition of aneurysm formation and
rupture.
Conclusions
In summary, we have demonstrated that TNF-α is in-
creased in both unruptured and ruptured cerebral aneu-
rysms in an in vivo model of cerebral aneurysm formation.
TNF-α expression was decreased in TNF-α knockout
mice, those pre-treated with the synthesized TNF-α in-
hibitor DTH, and controls versus unruptured and rup-
tured aneurysms. Additionally, the incidence of aneurysm
formation and rupture was significantly decreased in
TNF-α knockout mice and those pre-treated with DTH.
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sulted in aneurysm stabilization and markedly decreased
the incidence of rupture.
Additional file
Additional file 1: Quantitative real-time PCR, immunohistochemis-
try, and statistical analysis. Figure S1. TNF-α expression in TNF-α
knockout mice and those pretreated with DTH. Figure S2. Beta-actin
mRNA expression.
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